Kochnev’s leadership extends beyond the wellness industry—his approach to business growth, team empowerment, and market ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...

The researchers found that having ever used oral contraception reduced odds of ovarian cancer by 26% (odds ratio [OR], 0.74; ...

The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Bob Kierlin built Fastenal into a billion-dollar industry leader. His true legacy isn’t just Fastenal’s growth — it’s the ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...

A TASKFORCE will aim to allocate £2 million to a successful project in Ulverston by June as a ‘lasting legacy’ from a ...

After his success at the competition (and he went ... He spent a “career-changing” year in Philadelphia at what is now GlaxoSmithKline. By this stage, he and Mary had a young son and they ...